CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
Portfolio Pulse from
CROSSJECT has enhanced its collaboration with Eton Pharmaceuticals to develop a proprietary hydrocortisone formulation (ET-800) for the US hospital adrenal insufficiency market. The partnership involves CROSSJECT providing an innovative, ready-to-use liquid formulation that simplifies injection compared to current solutions. CROSSJECT will earn a high single-digit royalty on Eton's net sales, with product filings expected from the second half of 2026.
March 25, 2025 | 6:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eton is developing ET-800, a novel hydrocortisone injectable using CROSSJECT's formulation, targeting the $100M hospital market for adrenal insufficiency treatments.
The collaboration represents a significant product development opportunity for Eton, potentially expanding its rare disease treatment portfolio with an innovative injectable solution.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90